Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Paying user area

Try for free

Biogen Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Biogen Inc., consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Product, net
Revenues from anti-CD20 therapeutic programs
Other
Revenue
Cost of sales, excluding amortization and impairment of acquired intangible assets
Gross profit
Research and development
Selling, general and administrative
Amortization and impairment of acquired intangible assets
Collaboration (profit) loss sharing
Gain (loss) on divestiture of Hillerød, Denmark manufacturing operations
Gain (loss) on fair value remeasurement of contingent consideration
Acquired in-process research and development
Restructuring charges
Gain on sale of building
Income from operations
Other income (expense), net
Income before equity in income (loss) of investee and income tax (expense) benefit
Equity in income (loss) of investee, net of tax
Income before income tax (expense) benefit
Income tax (expense) benefit
Net income
Net (income) loss attributable to noncontrolling interests, net of tax
Net income attributable to Biogen Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Income statement item Description The company
Revenue Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Biogen Inc. revenue increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022.
Income from operations The net result for the period of deducting operating expenses from operating revenues. Biogen Inc. income from operations increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Income before income tax (expense) benefit Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Biogen Inc. income before income tax (expense) benefit increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Net income attributable to Biogen Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Biogen Inc. net income attributable to Biogen Inc. increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.